Search
Novartis' siRNA Therapy, Leqvio, Secures Expanded FDA Approval for Twice-Yearly Blood Lipid Reduction
9 hour ago /
Read about 0 minute
Author：小编
Novartis has announced that its innovative siRNA therapy, Leqvio (inclisiran), has garnered expanded approval from the U.S. Food and Drug Administration (FDA) for use as a monotherapy in patients suffering from hypercholesterolemia. This groundbreaking treatment necessitates just two subcutaneous injections annually and significantly lowers low-density lipoprotein cholesterol (LDL-C) levels. Developed globally by Novartis, with origins at Alnylam Pharmaceuticals, Leqvio's approval hinges on clinical trial data demonstrating its remarkable efficacy in both primary and secondary prevention of cardiovascular diseases. This new development offers patients a more flexible and convenient therapeutic alternative.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
